Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis

被引：21

作者：

Chong, Lip Leong ^{[1
]}

Soon, Yu Yang ^{[2
]}

Soekojo, Cinnie Yentia ^{[1
]}

Ooi, Melissa ^{[1
,4
]}

Chng, Wee Joo ^{[1
,3
,4
]}

de Mel, Sanjay ^{[1
]}

机构：

[1] Natl Univ Hlth Syst Singapore, Natl Univ Canc Inst Singapore, Dept Haematol Oncol, 1E Kent Ridge Rd, Singapore 119228, Singapore

[2] Natl Univ Hlth Syst Singapore, Natl Univ Canc Inst Singapore, Dept Radiat Oncol, Singapore, Singapore

[3] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore

[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2021年 / 159卷

关键词：

Daratumumab; Induction therapy; Newly diagnosed multiple myeloma; High cytogenetic risk; Meta-analysis;

D O I：

10.1016/j.critrevonc.2020.103211

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study aims to evaluate the efficacy and safety of Daratumumab-based induction therapy (DBI) in newly diagnosed multiple myeloma (MM). We identified four eligible RCTs including 2735 patients. The primary outcomes of RCTs involving transplant eligible (TEMM) and non-transplant eligible MM (NTEMM) were stringent complete response (sCR) and progression-free survival (PFS) respectively. Meta-analysis was performed using random-effects models. DBI improved sCR rates for standard risk (SR) (OR 1.86, 95 % CI 1.41-2.46) but not HiR (high risk) (OR 0.78, 95 % CI 0.41-1.48) (interaction P = 0.01) TEMM. In NTEMM, DBI improved PFS in SR (HR 0.44, 95 % CI 0.35-0.55) but not HiR patients. (HR 0.81, 95 % CI 0.52-1.27) (interaction P = 0.02). In conclusion, while DBI is efficacious in SR patients, there is insufficient data to support a benefit in HiR-MM.

引用

页数：7

共 21 条

[1] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study [J].

Bahlis, Nizar J. ;

Dimopoulos, Meletios A. ;

White, Darrell J. ;

Benboubker, Lotfi ;

Cook, Gordon ;

Leiba, Merav ;

Ho, P. Joy ;

Kim, Kihyun ;

Takezako, Naoki ;

Moreau, Philippe ;

Kaufman, Jonathan L. ;

Krevvata, Maria ;

Chiu, Christopher ;

Qin, Xiang ;

Okonkwo, Linda ;

Trivedi, Sonali ;

Ukropec, Jon ;

Qi, Ming ;

San-Miguel, Jesus .

LEUKEMIA, 2020, 34 (07) :1875-1884

[2] Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis [J].

Cao, Yaohua ;

Wan, Ning ;

Liang, Zhuoru ;

Xie, Jingmei ;

Wang, Sen ;

Lin, Tengfei ;

Zhang, Tiantian ;

Jiang, Jie .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (08) :E478-E488

[3] strmst2 and strmst2pw: New commands to compare survival curves using the restricted mean survival time [J].

Cronin, Angel ;

Tian, Lu ;

Uno, Hajime .

STATA JOURNAL, 2016, 16 (03) :702-716

[4] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, M. A. ;

Oriol, A. ;

Nahi, H. ;

San-Miguel, J. ;

Bahlis, N. J. ;

Usmani, S. Z. ;

Rabin, N. ;

Orlowski, R. Z. ;

Komarnicki, M. ;

Suzuki, K. ;

Plesner, T. ;

Yoon, S. -S. ;

Ben Yehuda, D. ;

Richardson, P. G. ;

Goldschmidt, H. ;

Reece, D. ;

Lisby, S. ;

Khokhar, N. Z. ;

O'Rourke, L. ;

Chiu, C. ;

Qin, X. ;

Guckert, M. ;

Ahmadi, T. ;

Moreau, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) :1319-1331

[5] Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma [J].

Facon, T. ;

Kumar, S. ;

Plesner, T. ;

Orlowski, R. Z. ;

Moreau, P. ;

Bahlis, N. ;

Basu, S. ;

Nahi, H. ;

Hulin, C. ;

Quach, H. ;

Goldschmidt, H. ;

O'Dwyer, M. ;

Perrot, A. ;

Venner, C. P. ;

Weisel, K. ;

Mace, J. R. ;

Raje, N. ;

Attal, M. ;

Tiab, M. ;

Macro, M. ;

Frenzel, L. ;

Leleu, X. ;

Ahmadi, T. ;

Chiu, C. ;

Wang, J. ;

Van Rampelbergh, R. ;

Uhlar, C. M. ;

Kobos, R. ;

Qi, M. ;

Usmani, S. Z. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22) :2104-2115

[6]

Gil-Sierra M.D., 2020, EUR J HAEMATOL

[7]

Laubach Jacob, 2016, Cancer Treat Res, V169, P145

[8] Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial [J].

Lonial, Sagar ;

Weiss, Brendan M. ;

Usmani, Saad Z. ;

Singhal, Seema ;

Chari, Ajai ;

Bahlis, Nizar J. ;

Belch, Andrew ;

Krishnan, Amrita ;

Vescio, Robert A. ;

Victoria Mateos, Maria ;

Mazumder, Amitabha ;

Orlowski, Robert Z. ;

Sutherland, Heather J. ;

Blade, Joan ;

Scott, Emma C. ;

Oriol, Albert ;

Berdeja, Jesus ;

Gharibo, Mecide ;

Stevens, Don A. ;

LeBlanc, Richard ;

Sebag, Michael ;

Callander, Natalie ;

Jakubowiak, Andrzej ;

White, Darrell ;

de la Rubia, Javier ;

Richardson, Paul G. ;

Lisby, Steen ;

Feng, Huaibao ;

Uhlar, Clarissa M. ;

Khan, Imran ;

Ahmadi, Tahamtan ;

Voorhees, Peter M. .

LANCET, 2016, 387 (10027) :1551-1560

[9] Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma [J].

Mateos, M. -V. ;

Dimopoulos, M. A. ;

Cavo, M. ;

Suzuki, K. ;

Jakubowiak, A. ;

Knop, S. ;

Doyen, C. ;

Lucio, P. ;

Nagy, Z. ;

Kaplan, P. ;

Pour, L. ;

Cook, M. ;

Grosicki, S. ;

Crepaldi, A. ;

Liberati, A. M. ;

Campbell, P. ;

Shelekhova, T. ;

Yoon, S. -S. ;

Iosava, G. ;

Fujisaki, T. ;

Garg, M. ;

Chiu, C. ;

Wang, J. ;

Carson, R. ;

Crist, W. ;

Deraedt, W. ;

Nguyen, H. ;

Qi, M. ;

San-Miguel, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (06) :518-528

[10] Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial [J].

Mateos, Maria-Victoria ;

Cavo, Michele ;

Blade, Joan ;

Dimopoulos, Meletios A. ;

Suzuki, Kenshi ;

Jakubowiak, Andrzej ;

Knop, Stefan ;

Doyen, Chantal ;

Lucio, Paulo ;

Nagy, Zsolt ;

Pour, Ludek ;

Cook, Mark ;

Grosicki, Sebastian ;

Crepaldi, Andre ;

Liberati, Anna Marina ;

Campbell, Philip ;

Shelekhova, Tatiana ;

Yoon, Sung-Soo ;

Iosava, Genadi ;

Fujisaki, Tomoaki ;

Garg, Mamta ;

Krevvata, Maria ;

Chen, Ying ;

Wang, Jianping ;

Kudva, Anupa ;

Ukropec, Jon ;

Wroblewski, Susan ;

Qi, Ming ;

Kobos, Rachel ;

San-Miguel, Jesus .

LANCET, 2020, 395 (10218) :132-141

← 1 2 3 →